Valeant Pharma strikes US$250-million friendly deal to buy Solta Medical

LAVAL, Que. – Valeant Pharmaceuticals International, Inc. (TSX:VRX) has a friendly deal to acquire Solta Medical, Inc. a California-based company that makes medical devices used in cosmetic surgery procedures.

The Montreal-area company’s offer of US$2.92 per share for all of Solta’s stock is valued at US$250 million, a 40 per cent premium to Friday’s closing price on Nasdaq.

Solta’s board of directors supports offer, which requires that Valeant gets at least a majority of Solta’s shares.

News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Canadian Press

The Canadian Press is Canada's trusted news source and leader in providing real-time, bilingual multimedia stories across print, broadcast and digital platforms.